-
Press Release
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
-
Press Release
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
-
Press Release
Novartis completes acquisition of Tourmaline Bio
-
Press Release
Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt
-
Press Release
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
-
Press Release
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
-
Press Release
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
-
Press Release
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
-
Press Release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
-
Press Release
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
-
Press Release
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
-
Press Release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)